“When Megan Callahan was growing up, she was supposed to end up in healthcare— she didn’t even know there were alternatives. And she has spent her career and life in and around the field in more ways than she ever expected, as both an executive and a breast cancer patient. What ...
“The narrowing of issues and limitation to original theories and arguments as a case ascends the appellate ladder would seem to be a bedrock principle. And yet … We wouldn’t be raising this general proposition at all unless there were exceptions.”
“With confidence he attributes to his free-range childhood, Chris Gibson has followed his instincts and his heart, stepping away from the MD/PhD program in which he’s enrolled to co-found and lead Recursion Pharmaceuticals, one of the buzziest companies bringing AI to drug development. ...
In Iancu v. Brunetti,1 the U.S. Supreme Court ruled that a federal ban on the registration of immoral or scandalous trademarks like FUCT (pronounced as F-U-C-T) violated the First Amendment. By a 6–3 vote, the Court ruled that the ban was unconstitutional because it discriminated based on ...
“The sudden attention to cryptocurrency and digital assets is striking after a few years of uncertainty and a fragmented regulatory environment that has left many investors vulnerable to fraudsters, hacking, lost passwords and unrecoverable assets in blockchain investing. The natural result ...
Manatt’s Benjamin Chu, a senior advisor with Manatt Health, and Jared Augenstein, a senior manager with Manatt Health, wrote a piece for FierceHealthcare on the components of a successful telehealth program.
Manatt’s Lisa Suennen, leader of the firm’s digital and technology group, spoke with healthcare entrepreneur Sumit Nagpal for her podcast Tech Tonics on technology as a key driver of innovation, and how that impacts the health industry.
“The dead heat between Tiffany Cabán and Melinda Katz in the Democratic primary for Queens district attorney — now amid a full manual recount — has befuddled many political pundits. Still, much can be gleaned from this veritable kaleidoscope of Queens politics.”
In Return Mail Inc. v. U.S. Postal Service,1 in a 6-to-3 ruling, the Supreme Court held a federal agency is not a “person” authorized to petition for review of the validity of a patent, and therefore a federal agency cannot utilize the three types of administrative review proceedings ...
“Sorry for the bait-and-switch title, but this article is not about what you probably think it’s going to be about. Rather, we’re here to discuss when is it appropriate to ride someone else’s coattails in appellate proceedings.”